H. pylori & Alzheimer’s
TL;DR: H. pylori is associated with a modest increase in all-cause dementia risk (RR ~1.4–1.7), but the association with Alzheimer’s disease specifically is inconsistent across meta-analyses and weakens or disappears in the best-powered and most recent analyses. H. pylori has never been detected in AD brain tissue — it was explicitly used as a negative control in the landmark P. gingivalis brain study (Dominy 2019). No RCT has demonstrated that H. pylori eradication prevents or treats AD. The most clinically actionable element is B12 deficiency, which is independently linked to cognitive decline and is correctable regardless of H. pylori status.
Why It Matters for Vitals
- B12 deficiency — most actionable pathway: H. pylori can impair gastric acid and intrinsic factor production, reducing B12 absorption. B12 deficiency causes elevated homocysteine and reversible cognitive symptoms. Testing B12/methylmalonic acid/homocysteine is more actionable than pathogen targeting.
- Inflammatory biomarker confound: H. pylori gastritis elevates systemic IL-6, TNF-α — overlapping with Vitals recovery biomarker tracking. May contribute to elevated CRP baselines in some users.
- Eradication therapy effects: The antibiotic + PPI regimens used for H. pylori eradication cause GI disruption and microbiome effects that may transiently affect recovery biometrics.
- Wearable actionability: very low — no consumer wearable detects H. pylori activity or its CNS effects. The practical Vitals action is B12 monitoring and standard GI indication testing, not pathogen-directed cognitive protection.
Key Facts
| Fact | Detail | Evidence Grade |
|---|---|---|
| H. pylori NOT in AD CSF | Negative in all 10 AD patient CSF samples (Dominy 2019 — same study that detected P. gingivalis in 7/10) | A |
| Association with all-cause dementia | RR 1.4–1.7 (multiple meta-analyses); more consistent than AD-specific association | B |
| Association with AD specifically | Inconsistent; recent meta-analyses find no significant AD-specific link; only all-cause dementia | B–C |
| NHANES prospective (n=1,608) | HR 0.98 (not significant) — the most rigorous design found no association | B |
| OMV-C3-C3aR mechanism | Mouse/in-vitro only; H. pylori OMVs cross BBB in mice, drive complement activation, Aβ deposition | B (animal) |
| B12 deficiency pathway | H. pylori contribution to B12 deficiency is real and clinically proven | B |
| Eradication RCT for AD | One small open-label trial (Kountouras 2009, n=106); no double-blind replication | B– |
Mechanism Summary
OMV-Mediated CNS Effects (Preclinical Only)
H. pylori outer membrane vesicles cross the blood-brain barrier in mice (tracked via DiD fluorescence), are taken up primarily by astrocytes, and drive complement C3 upregulation and C3aR activation in glial cells. This leads to synaptic dysfunction and Aβ deposition in APP/PS1 mice. LPC 18:0 lipid enriched in H. pylori OMVs directly accelerates Aβ aggregation in vitro. See Bacterial OMVs.
Critical caveat: No study has detected H. pylori OMVs, DNA, or antigens in human brain tissue or CSF. This mechanism is entirely preclinical. See ~OMV Brain Crossing.
Systemic Inflammation
Chronic H. pylori gastritis elevates systemic IL-6, TNF-α. This overlaps with inflammatory pathways tracked in Vitals recovery monitoring. The inflammatory burden may contribute to vascular cognitive impairment rather than direct AD-type amyloid/tau pathology.
B12 Deficiency Pathway (Most Evidence-Supported)
H. pylori suppresses gastric acid and intrinsic factor production → impaired B12 absorption → elevated homocysteine → neurotoxicity. This mechanism is proven for B12 deficiency and H. pylori’s contribution to B12 deficiency is well-established. B12 deficiency is independently linked to cognitive decline and is correctable — this is the most actionable element of the H. pylori → cognitive decline hypothesis.
The Negative Control Problem
In Dominy 2019 (PMID:30746447), H. pylori was explicitly included as a negative control pathogen. It was tested in CSF from 10 AD patients and was negative in all 10 samples. P. gingivalis was positive in 7/10. This suggests H. pylori does not share P. gingivalis’s brain access capability, or does so at levels below detection.
What the Evidence Suggests
What is supported:
- H. pylori is associated with all-cause dementia (RR ~1.4–1.7) — modest, consistent, but susceptible to confounding
- H. pylori contribution to B12 deficiency is real and clinically actionable
- The OMV-C3-C3aR mechanism is biologically plausible in mice
- Association with AD specifically is weaker than for dementia broadly
What is NOT supported:
- H. pylori is a proven cause of AD — association is inconsistent for AD specifically
- H. pylori has been detected in AD brain tissue — the opposite is true (negative in all AD CSF samples tested)
- H. pylori eradication prevents or treats AD — no large RCT confirms this
- OMVs cross the human BBB — this has never been demonstrated in humans
- The AD-specific association survives the best-powered recent meta-analyses — it does not
The prevalence paradox: H. pylori infects ~44% of the global population; AD affects ~10% of over-65s. If H. pylori were causally responsible for a substantial fraction of AD cases, the population attributable fraction would produce far higher effect sizes than the RR of 1.4–1.7 observed.
Risks and Uncertainty
- No brain detection — H. pylori was explicitly negative in AD CSF (Dominy 2019), the only study to directly test this
- No AD-specific eradication RCT — the one available trial was small, open-label, and not replicated
- Residual confounding — SES, healthcare access, diet, smoking all drive both H. pylori acquisition and AD risk
- Dementia ≠ AD — many positive studies measured all-cause dementia, which has a broader inflammatory etiology
- Modest ORs (1.4–1.7) are precisely in the range most susceptible to confounding
- Prevalence paradox — too common to specifically drive AD in most infected individuals
- Eradication therapy risks — clarithromycin has significant CYP3A4 drug interactions; antibiotic resistance is common
Wearable / Vitals Relevance
| Signal | Current Status | Confidence |
|---|---|---|
| HRV | No data | C (speculative) |
| Sleep | No direct data | C (speculative) |
| CRP/IL-6 | Elevated in H. pylori gastritis; may confound recovery baselines | B |
| B12/homocysteine | Correctable biomarker; directly relevant to cognitive function | B |
| Wearable detection of H. pylori | Not possible with current consumer devices | N/A |
Practical Vitals implication: B12 testing (serum B12, methylmalonic acid, homocysteine) is more actionable than pathogen-directed testing for cognitive protection purposes. H. pylori testing should be driven by standard GI/B12 clinical indications, not AD prevention.
Best Stack Context
- H. pylori / AD is relevant primarily as a B12 deficiency indicator and an inflammatory baseline confound
- It is NOT a primary target for any current Vitals coaching protocol
- Do not recommend H. pylori eradication specifically for AD prevention
- B12 optimization is actionable for any user with cognitive concerns, independent of H. pylori status
- For users on long-term PPI therapy: B12 deficiency risk is elevated regardless of H. pylori status — monitor accordingly
What Not to Recommend
- ❌ H. pylori eradication specifically for AD prevention — no RCT evidence
- ❌ Mastic gum or supplements targeting H. pylori for cognitive purposes — no human evidence
- ❌ Stopping standard AD medications based on H. pylori data
- ❌ Serology alone for active infection detection (cannot distinguish past from current infection)
Related Notes
- Helicobacter pylori — comprehensive H. pylori hub note
- Periodontal Pathogens — P. gingivalis hub (related AD pathogen hypothesis)
- Gingipain — P. gingivalis gingipain mechanism
- Bacterial OMVs — OMV mechanism shared between P. gingivalis and H. pylori
- Infectious Agents MOC — navigation hub for infectious disease hypotheses
- ~OMV Brain Crossing — aspirational note for human OMV BBB translation (not created yet — preclinical only)
- ~B12-Cognitive Protocol — aspirational note for B12 optimization protocol (would belong in 04-Protocols-and-Recovery)
References
- PMID:30746447 — Dominy et al. 2019, Sci Adv (H. pylori negative control in AD CSF)
- PMID:40958121 — Elhady et al. 2025, Eur J Med Res (no AD-specific link; bidirectional dementia)
- PMID:34559067 — Liu et al. 2021, Aging (meta-analysis; no significant AD-specific association)
- PMID:18378629 — Beydoun et al. 2008, NHANES prospective (HR 0.98, NS)
- PMID:36792546 — Xie et al. 2023, J Extracell Vesicles (OMV → C3-C3aR in mice)
- PMID:39516239 — Meng et al. 2024, Commun Biol (OMV → Aβ in APP/PS1 mice)
- PMID:19240960 — Kountouras et al. 2009, J Neurol (small open-label eradication RCT)
- PMID:31026327 — Huang et al. 2019 (meta-analysis; all-cause dementia)